Upstart ( NASDAQ: UPST) expects $587.3 million in net proceeds ($675.5 million if the option is exercised). About $48 million ...

Discover key takeaways from Macerich's Q2 2025 earnings call, including leasing milestones, strategic acquisitions, and progress on the Path Forward plan.

Discover AST SpaceMobile's Q2 2025 earnings insights: satellite milestones, $1.5B funding, commercialization progress, and a $50-$75M H2 revenue target.

Gain insights into FibroGen’s Q2 2025 earnings call, highlighting trial progress, regulatory updates, and increased cash runway.

IPO trends, insights on insider selling, and potential opportunities for contrarian investors amid. See more on INR stock.

Discover key insights from Xenon Pharmaceuticals' Q2 2025 earnings call, including milestones in epilepsy, depression trials, and a strong cash ...

OneMain's prudent loan split and conservative growth strategies position it well for future rate cycles. See how OMF stock's ...

Discover key Q2 2025 insights on Gaia, Inc. (GAIA), including 12% revenue growth, AI advancements, and Igniton's launch.

Belite Bio (BLTE) reports strong Q2 2025 progress on Tinlarebant trials for Stargardt's disease & geographic atrophy.

Discover Maravai LifeSciences' Q2 2025 earnings insights: restructuring plans, cost-cutting moves saving $50M+, and a roadmap to profitability by 2026.

Maravai LifeSciences Holdings, Inc. ( NASDAQ: MRVI) Q2 2025 Earnings Conference Call August 11, 2025 5:00 PM ET Bernd Brust - CEO & Director Debra Hart - Senior Director of Investor Relations Rajesh J ...

lululemon's stock has dropped so much because the board is numbers-driven and there's nobody looking after the creative side.